» Articles » PMID: 31209475

Evidence for Enhanced Bruton's Tyrosine Kinase Activity in Transitional and Naïve B Cells of Patients with Granulomatosis with Polyangiitis

Overview
Specialty Rheumatology
Date 2019 Jun 19
PMID 31209475
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To determine Bruton's tyrosine kinase (BTK) protein and phosphorylation levels in B cell subsets of granulomatosis with polyangiitis (GPA) patients and to investigate the effect of BTK blockade on in vitro B cell cytokine production, subset distribution and (auto)antibody production.

Methods: BTK protein and phosphorylation levels were determined by flow cytometry in peripheral blood B cells of 29 untreated GPA patients [9 active and 20 remission GPA patients (10 ANCA- and 10 ANCA+)], 9 age- and sex-matched healthy controls (HCs) and 9 untreated active RA patients. The effect of BTK blockade on in vitro B cell cytokine production, subset distribution and (auto)antibody production was determined in the same donors in peripheral blood mononuclear cell cultures.

Results: BTK protein levels were significantly increased in transitional and naïve B cells of active GPA and RA patients compared with remission GPA patients and HCs. Both B cell subsets of active patients were more sensitive to B cell receptor stimulation, as BTK and phospholipase Cγ2 phosphorylation were increased in these patients. In vitro BTK blockade had profound effects on B cell cytokine production, plasma cell formation and (auto)antibody production in both GPA patients and HCs. Interestingly, the effect of BTK blockade was less pronounced in active GPA patients, possibly due to increased activation of B cells.

Conclusion: We show that BTK protein and phosphorylation levels are most profoundly increased in newly emerging B cells of active GPA patients compared with remission patients. BTK blockade greatly inhibits in vitro B cell effector functions in GPA patients and HCs. These promising data identify BTK as an interesting novel therapeutic target in the treatment of GPA.

Citing Articles

Aberrant B cell receptor signaling responses in circulating double-negative 2 B cells from radiographic axial spondyloarthritis patients.

Wilbrink R, Neys S, Hendriks R, Spoorenberg A, Kroese F, Corneth O J Transl Autoimmun. 2025; 10:100270.

PMID: 39974741 PMC: 11835616. DOI: 10.1016/j.jtauto.2025.100270.


Combination treatment with telitacicept, cyclophosphamide and glucocorticoids for severe Granulomatous polyangiitis: a case report and literature review.

Huang L, Lin W, Liu Y, Zhu J, Li Y, Zheng Z Front Immunol. 2023; 14:1298650.

PMID: 38106422 PMC: 10722187. DOI: 10.3389/fimmu.2023.1298650.


Human B-cell subset identification and changes in inflammatory diseases.

Velounias R, Tull T Clin Exp Immunol. 2023; 210(3):201-216.

PMID: 36617261 PMC: 9985170. DOI: 10.1093/cei/uxac104.


Therapeutic effect of ibrutinib, a selective Bruton's tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves' orbitopathy.

Park H, Chae M, Ko J, Kikkawa D, Jang S, Yoon J PLoS One. 2022; 17(12):e0279060.

PMID: 36521376 PMC: 9754806. DOI: 10.1371/journal.pone.0279060.


Aberrant B Cell Signaling in Autoimmune Diseases.

Corneth O, Neys S, Hendriks R Cells. 2022; 11(21).

PMID: 36359789 PMC: 9654300. DOI: 10.3390/cells11213391.


References
1.
Corneth O, Verstappen G, Paulissen S, de Bruijn M, Rip J, Lukkes M . Enhanced Bruton's Tyrosine Kinase Activity in Peripheral Blood B Lymphocytes From Patients With Autoimmune Disease. Arthritis Rheumatol. 2017; 69(6):1313-1324. DOI: 10.1002/art.40059. View

2.
Rip J, van der Ploeg E, Hendriks R, Corneth O . The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity. Crit Rev Immunol. 2018; 38(1):17-62. DOI: 10.1615/CritRevImmunol.2018025184. View

3.
de Joode A, Sanders J, Rutgers A, Stegeman C . Maintenance therapy in antineutrophil cytoplasmic antibody-associated vasculitis: who needs what and for how long?. Nephrol Dial Transplant. 2015; 30 Suppl 1:i150-8. DOI: 10.1093/ndt/gfu397. View

4.
Little M, Nightingale P, Verburgh C, Hauser T, Groot K, Savage C . Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis. 2009; 69(6):1036-43. DOI: 10.1136/ard.2009.109389. View

5.
Leavitt R, Fauci A, Bloch D, Michel B, Hunder G, Arend W . The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum. 1990; 33(8):1101-7. DOI: 10.1002/art.1780330807. View